Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


April 27, 2015 12:24 AM ET

Biotechnology

Company Overview of Chroma Therapeutics Ltd.

Company Overview

Chroma Therapeutics Ltd. operates as a biotechnology company. The company focuses on chromatin biology and novel drug accumulation approaches to discover and develop cancer and inflammation treatments, and small molecule drugs. The company was incorporated in 2000 and is based in Abingdon, United Kingdom.

93 Innovation Drive

Milton Park

Abingdon,  OX14 4RY

United Kingdom

Founded in 2000

Phone:

44 1235 829120

Fax:

44 1235 829125

Key Executives for Chroma Therapeutics Ltd.

Chief Executive Officer and Director
Age: 45
Founder,Chairman of Scientific Advisory Board and Director
Founder and Member of Scientific Advisory Board
Age: 56
Founder and Member of Scientific Advisory Board
Chief Medical Officer
Compensation as of Fiscal Year 2014.

Chroma Therapeutics Ltd. Key Developments

CTI Acquires Exclusive Worldwide License to Tosedostat Through Concurrent Transactions with Vernalis R&D Limited and Chroma Therapeutics Ltd

CTI BioPharma Corp. announced that it has acquired worldwide rights to tosedostat through concurrent transactions with Vernalis R&D Limited and Chroma Therapeutics Ltd. Tosedostat is a first-in-class selective inhibitor of aminopeptidases, which are required by tumor cells to provide amino acids necessary for growth and tumor cell survival. Tosedostat is currently being evaluated in multiple Phase 2 clinical trials for the treatment of patients with Acute Myeloid Leukemia (AML) or high-risk Myelodysplastic Syndrome (MDS), which are intended to inform the design for a Phase 3 registration study to support potential regulatory approval. Over the next year, CTI and its advisors intend to develop a registration path for tosedostat in the US and Europe. Chroma and CTI also terminated their prior license agreement relating to tosedostat, thereby eliminating potential future developmental and sales milestone payments by CTI of up $209 million thereunder. Concurrently, CTI entered into a license agreement with Vernalis for the exclusive worldwide right to use certain patents and other intellectual property rights to develop, market and commercialize tosedostat and certain other analogues. Under the Vernalis license agreement, CTI agreed to make tiered royalty payments of no more than a high single-digit percentage, on a country-by-country basis, for the longer of ten years following commercial launch or the expiration of relevant patents.

Similar Private Companies By Industry

Company Name Region
CellCentric Ltd. Europe
Sygnature Discovery Limited Europe
Piramed Limited Europe
Applied Biosystems Holdings Limited Europe
Genex Biosystems ltd Europe

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
October 27, 2014
Chroma Therapeutics Ltd., Worldwide Rights to Tosedostat
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Chroma Therapeutics Ltd., please visit www.chromatherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.